CDNA vs. GTH, PSNL, GH, FTRE, VCYT, VRDN, CSTL, FLGT, CELC, and SERA
Should you be buying CareDx stock or one of its competitors? The main competitors of CareDx include Genetron (GTH), Personalis (PSNL), Guardant Health (GH), Fortrea (FTRE), Veracyte (VCYT), Viridian Therapeutics (VRDN), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), and Sera Prognostics (SERA). These companies are all part of the "medical" sector.
Genetron (NASDAQ:GTH) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
10.7% of Genetron shares are owned by institutional investors. 4.2% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CareDx received 427 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 66.72% of users gave CareDx an outperform vote while only 33.33% of users gave Genetron an outperform vote.
Genetron has a net margin of 0.00% compared to Genetron's net margin of -66.59%. CareDx's return on equity of 0.00% beat Genetron's return on equity.
Genetron has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, CareDx has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.
In the previous week, CareDx had 9 more articles in the media than Genetron. MarketBeat recorded 9 mentions for CareDx and 0 mentions for Genetron. Genetron's average media sentiment score of 0.58 beat CareDx's score of 0.00 indicating that CareDx is being referred to more favorably in the news media.
CareDx has a consensus price target of $16.50, indicating a potential upside of 2.17%. Given Genetron's higher possible upside, analysts plainly believe CareDx is more favorable than Genetron.
Genetron has higher earnings, but lower revenue than CareDx.
Summary
CareDx beats Genetron on 10 of the 15 factors compared between the two stocks.
Get CareDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
